In both Alzheimer’s disease (AD) and Parkinson’s disease (PD), antibody-based therapies targeting pathological aggregates, such as amyloid-β (Aβ) and α-synuclein (α-syn), have shown potential in reducing biomarkers like amyloid plaques and pathological aggregates. This evidence concerns the gene SNCA and Parkinson disease.